S-1 and Docetaxel for Metastatic Gastric Cancer
Author Information
Author(s): Park S R, Kim H K, Kim C G, Choi I J, Lee J S, Lee J H, Ryu K W, Kim Y-W, Bae J-M, Kim N K
Primary Institution: National Cancer Center, Republic of Korea
Hypothesis
To determine the maximum tolerated dose and evaluate the efficacy and toxicity of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Conclusion
S-1 combined with weekly docetaxel is active in metastatic gastric carcinoma with moderate toxicities.
Supporting Evidence
- The overall response rate was 66.7%.
- The median time to progression was 6.5 months.
- The median overall survival was 13.7 months.
- Neutropenia was the most common grade 3/4 toxicity at 29.4%.
- One treatment-related death occurred due to pneumonitis.
Takeaway
This study tested a new cancer treatment for stomach cancer and found it works well but can cause some side effects.
Methodology
Patients received S-1 orally and docetaxel intravenously in a phased trial to determine dosage and effectiveness.
Potential Biases
Potential biases may arise from the single-institution study design and patient selection criteria.
Limitations
The study had a limited sample size and was conducted in a specific patient population.
Participant Demographics
The study included 30 patients in phase I and 52 in phase II, with a median age of 50 years in phase I and 53 years in phase II.
Statistical Information
P-Value
0.0366
Confidence Interval
95% CI: 53.8–79.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website